NEW YORK, May 3, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
Triple Analysis: Leukemia, Lung Cancer and Angiogenesis
http://www.reportlinker.com/p0284981/Triple-Analysis-Leukemia-Lung-Cancer-and-Angiogenesis.html
This triple analysis focuses on cancer drug development strategies in both Leukemia and Lung Cancer and by the mechanism/target/effect of Angiogenesis. Each of these three individual parts is evaluated according to standardized criteria in a five pillar pipeline drug assessment methodology to compare drug development strategies in oncology. This makes it easy to find and compare analysis not only within one single cancer focus area but also between different areas.
Below is a short synopsis of each part included in this report:
Part I: Leukemia
The leukemia report part comprises defined and up to date development strategies for 313 leukemia drugs within the portfolio of 186 investigators, from Ceased to Marketed. This part extensively analyses their 204 identified drug targets, organized into 193 drug target strategies, and assesses them in eight different compound strategies and eight subindications of leukemia.
This part is based on the following publication:
A Decision Support Tool for Optimizing The Leukemia Pipeline: From Research and Development to Market
Part II: Lung Cancer
The lung cancer report part includes defined and up to date development strategies for 283 lung cancer therapeutic drugs (>317 projects) within the portfolio of 167 investigators, from Ceased to Marketed. In total the report assesses three different sub-indications of lung cancer (Non-Small Cell Lung Cancer, Small Cell Lung Cancer and Lung Cancer (general). This report part extensively analyses 182 identified targets of lung cancer drugs, organized into 173 drug target strategies, and assesses them in lung cancer.
This part is based on the following publication:
Competitive Outlook on Lung Cancer Drug Development - The Missing Handbook to New Product Planning and Portfolio Planning
Part III: Angiogenesis
The angiogenesis report part comprises defined and up to date development strategies for 239 drugs affecting angiogenesis in oncology within the portfolio of 148 investigators, from Preclinical to Marketed. This report part extensively analyses 174 identified targets of angiogenesis affecting drugs, organized into 167 drug target strategies, and assesses them in 64 different cancer indications.
This part is based on the following publication:
Commercializing Cancer Drugs Affecting Angiogenesis: A Decision Support Tool for Optimizing the Pipeline
The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development strategies for your own portfolio products. It helps teams to maximize molecule value by selecting optimal development plans and manage risk and uncertainty. The report serves as an external commercial advocate for pharmaceutical companies' pipeline and portfolio planning (PPP) in cancer by:
* Providing you with competitive input to the R&D organization to guide development of early product ideas and ensure efforts are aligned with business objectives
* Assisting you to make informed decisions in selecting cancer indications that are known to be appropriate for your drug's properties
* Analyzing, correlating and integrating valuable data sources in order to provide accurate data for valuation of pipeline, in-licensing and new business opportunities
* Providing you with commercial analytic support for due diligence on in-licensing and acquisition opportunities
* Supporting development of integrative molecule, pathway and disease area strategies
* Integrating knowledge for you to consider the therapeutic target for the highest therapeutic outcome and return on investment
This report provides systems, analytical and strategic support both internally to PPP and to stakeholders across your own organization. The report will also be an important part of creating and implementing a market development plan for cancer drugs to insure that the optimal market conditions exist by the time the products are commercialized.
Key Topics Covered:
Part I: Leukemia
5.1 The Scope of this Report 29
6 Consider the Therapeutic Target Among Leukemia Drugs for the Highest Therapeutic Outcome and Return on Investment (204 Drug Targets) 33-443
7 Emerging New Products to Established Ones: Drug Target Strategies of Leukemia Drugs by their Highest Stage of Development (193 Drug Target Strategies and 313 Leukemia Drugs) 444-727
8 Compound Strategies at Work: Competitive Benchmarking of Leukemia Drugs by Compound Strategy (8 Compound Strategies) 679-728
9 Selecting Subindication for Leukemia Drugs (8 Subindications of Leukemia) 729-762
10 Pipeline and Portfolio Planning: Competitive Benchmarking of the Leukemia Drug Pipeline by Investigator (186 Companies) 763-1,129
11 Disclaimer 1130
12 Drug Index 1131
13 Company Index 1140
Figures: Includes 6 Figures
Tables: Includes 253 Tables
Total Number of Pages: 1,147
Part II: Lung Cancer
5.1 The Scope of this Report 27
6 Consider the Therapeutic Target for the Highest Therapeutic Outcome and Return on Investment (182 Drug Targets) 31-323
7 The Rise of New Products: How Mature, Unique and Clinically Validated are the Drug Target Profiles Identified in the Lung Cancer Pipeline? (173 Drug Target Strategies and 283 Drugs) 324-368
8 Compound Strategies at Work: Competitive Benchmarking of Lung Cancer Pipeline by Type of Compound (7 Different Compound Strategies) 369-419
9 Selecting a Sub-Indication of Lung Cancer for Drug Development 420-462
10 Portfolio Planning: Competitive Benchmarking of Lung Cancer Pipeline by Investigator (167 Investigators) 463-751
12 Drug Index 753
13 Company Index 761
Figures: Includes 13 Figures
Tables: Includes 227 Tables
Total Number of Pages: 596
Part III: Angiogenesis
5.1 The Scope of this Report 35
6 Consider the Therapeutic Target for the Highest Therapeutic Outcome and Return on Investment (174 Drug Targets) 39-366
7 Emerging New Products to Established Ones: Drug Target Strategies of Cancer Drugs Affecting Angiogenesis by their Highest Stage of Development (167 Drug Target Strategies and 239 Drugs) 367-437
8 Compound Strategies at Work: Competitive Benchmarking of Cancer Drugs Affecting Angiogenesis by Compound Strategy (7 Different Compound Strategies) 438-485
9 Selecting Cancer Indications for Angiogenesis Affecting Drugs in Oncology (64 Cancer Indications) 486-643
10 Pipeline and Portfolio Planning: Competitive Benchmarking of the Angiogenesis Affecting Drug Pipeline in Oncology by Investigator (148 Investigators) 644-1211
10 Disclaimer 1212
11 Drug Index 1213
12 Company Index 1221
Figures: Includes 7 Figures
Tables: Includes 300 Tables
Total Number of Pages: 1227
To order this report:
Triple Analysis: Leukemia, Lung Cancer and Angiogenesis
Check our Company Profile, SWOT and Revenue Analysis!
CONTACT:
Nicolas Bombourg
Reportlinker
Email: [email protected]
US: +1-805-652-2626
Intl: +1-805-652-2626
SOURCE Reportlinker